Xdr-Tb Can Be Treated

More than 60 percent of HIV-negative XDR -TB patients in the study, which was conducted in home and community-based settings in Peru...

Once thought to be incurable, extensively drug-resistant tuberculosis (XDR-TB) can be treated in some patients, if they are not co-infected with HIV and have access to comprehensive care, according to a study published in the August 7 issue of the New England Journal of Medicine (NEJM). More than 60 percent of HIV-negative XDR -TB patients in the study, which was conducted in home and community-based settings in Peru between 1999 and 2002, were successfully treated using a combination of free, individualized drug treatment and additional services, such as surgery, adverse-event management, and nutritional and psychological support.

"It's essential that the world know that XDR-TB is not a death sentence," says lead author Carole Mitnick, a Harvard Medical School instructor in global health and social medicine. The results from Peru, which were even better than some XDR-treatment results in hospitals in Europe, the United States, and Korea, demonstrate that even in settings where there are limited resources, XDR-TB can be cured in many cases on an outpatient basis.

Writing in the same issue of NEJM, Mario C. Raviglione, head of the Stop TB Department of the World Health Organization, praised the study for changing the perception that XDR-TB is untreatable. He cautioned, however, that the high rate of successful treatment in Peru may not be reproducible elsewhere; a strain of XDR-TB reported in Italy, for example, is resistant to all available drugs. And the local capacity for TB treatment in Peru may be exceptional, because it results from cooperation among HMS, the Harvard School of Public Health, Brigham and Women's Hospital, the Massachusetts State Laboratory Institute, and the Lima, Peru-based organizations Socios en Salud, the Hospital Nacional Sergio Bernales, and the Peruvian Ministry of Health.

The question and the challenge now, writes Raviglione, is whether this model of treatment can be scaled up—not just nationally in Peru, but globally.

For more about the global threat of tuberculosis, see "A Plague Reborn."

 

 

 

Related topics

You might also like

What Happens When Infections Stop Responding to Antibiotics?

Harvard Medical School experts discuss the growing threat of antimicrobial resistance.

Green AI: Hype or Hope?

An expert panel explores AI’s climate impact, from emissions to water use.

Five Questions with Javier Ortega-Hernández

A professor of evolutionary biology on what shaped life more than 500 million years ago

Most popular

Harvard’s Finances In a Challenging Year

The fiscal 2024 report details narrowing margins, but stronger endowment returns.

Harvard Art Historian Jennifer Roberts Teaches the Value of Immersive Attention

Teaching students the value of deceleration and immersive attention

Harvard Football: Harvard 59, Holy Cross 24

Another week, another blowout, this one against an in-state rival

Explore More From Current Issue

James Muller in white lab coat leaning on railing in hospital hallway.

Free Speech, the Bomb-and Donald Trump

A Harvard cardiologist on the unlikely alliances that shaped a global movement to prevent nuclear war

Man splashing water on his face at outdoor fountain beside woman holding cup near stone building.

Why Heat Waves Make You Miserable

Scientists are studying how much heat and humidity the human body can take.

Room filled with furniture made from tightly rolled newspaper sheets.

A Paper House In Massachusetts

The 1920s Rockport cottage reflects resourceful ingenuity.